Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02958930 · ClinicalTrials.gov registry record · NA
Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease
A NA study of Alzheimer Disease and Alzheimer Disease, Late Onset, sponsored by NeuroEM Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02958930: Completed NA study of Alzheimer Disease and Alzheimer Disease, Late Onset, sponsored by NeuroEM Therapeutics.
NCT02958930 is a NA study of Alzheimer Disease and Alzheimer Disease, Late Onset that has completed, run by NeuroEM Therapeutics. The registered enrollment target is 8 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02958930, a NA study of Alzheimer Disease and Alzheimer Disease, Late Onset, has completed, sponsored by NeuroEM Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and initial efficacy of Transcranial Electromagnetic Treatment (TEMT) in patients with mild/moderate Alzheimer's Disease. Throughout a 2-month treatment period, patients will be evaluated for cognitive performance, brain energy utilization, functional brain imaging, and blood/cerebrospinal fluid (CSF) markers for Alzheimer's Disease. Since all patients will receive TEMT, each patient's baseline measurements will serve as their own control for any treatment effects.
Primary Outcome
ADAS-Cog is the standard/benchmark test of cognitive performance evaluated in Alzheimer's-related clinical trials.
Conditions Studied
Interventions
- DEVICE MemorEM 1000
Study Locations (1)
Florida
- Byrd Alzheimer's Institute, University of South Florida - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2019-01-11 |
| Phase | NA |
What the finished NCT02958930 record still lists
NCT02958930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which MemorEM 1000 is the first listed.
NCT02958930 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02958930 about?
NCT02958930 is a clinical study titled "Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease". The purpose of this study is to determine the safety and initial efficacy of Transcranial Electromagnetic Treatment (TEMT) in patients with mild/moderate Alzheimer's Disease. Throughout a 2-month treatment period, patients will be evaluated for cognitive performance, brain energy utilization, functi...
What is the current status of trial NCT02958930?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2017-10-01. Estimated completion is 2019-01-11.
What conditions does trial NCT02958930 study?
This clinical trial studies the following conditions: Alzheimer Disease, Alzheimer Disease, Late Onset.
What interventions are being tested in trial NCT02958930?
The interventions under investigation include: MemorEM 1000 (DEVICE).
Who is sponsoring clinical trial NCT02958930?
This trial is sponsored by NeuroEM Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02958930 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02958930's enrollment target sits among peer trials
8 296th of 306 higher than 8 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI